source
- FDA approves Tregzi, first T‑reg cell therapy to lower chronic GVHD risk in blood‑cancer transplantsThe FDA announced approval of Tregzi, a regulatory T‑cell based immunotherapy designed to improve chronic graft‑versus‑host disease‑free survival for adults with blood cancers undergoing allogeneic…
- Anthropic to launch its own drug-development program using Claude Science AIAnthropic, an AI company best known for its Claude models, announced it will begin developing its own drug candidates. Executives said the effort is meant to give the firm hands-on experience appl…